1. Home
  2. Directory
  3. Massachusetts
  4. Boston
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1245857028

MS. LINDA ANN COTTER NP-C
Prescription History 1245857028
Nurse Practitioner - Adult Health in Boston, MA

NPI Status: Active since June 29, 2020

Contact Information

800 WASHINGTON ST
BOSTON, MA
ZIP 02111
Phone: (617) 636-2273

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. LINDA ANN COTTER NP-C, an active Adult Health specialist practicing in Boston, MA. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 225 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 80 claims alone.

Medication Index

A
D
E
F
M
X
No matching medications currently found on file.

Amiodarone Hcl

Generic Formulation: Amiodarone HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 77.8
Days Supply 2,318
MA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills65.5
Peer Average Days Supply1,894
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $854.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.55

State Avg Cost Per Claim

$40.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as recurrent ventricular fibrillation/tachycardia). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. Amiodarone is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat.

Dofetilide

Generic Formulation: DofetilideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 28.0
Days Supply 840
MA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills53.7
Peer Average Days Supply1,597
Conservative Utilization

This provider writes prescriptions for this formulation 37.5% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,477.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$431.82

State Avg Cost Per Claim

$485.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as atrial fibrillation/flutter). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. Dofetilide is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat. Treating an irregular heartbeat can decrease the risk for blood clots, and this effect can reduce your risk of heart attack or stroke.

Eliquis

Generic Formulation: ApixabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 80
30-Day Fills 159.7
Days Supply 4,790
MA State Average Benchmarks
Peer Average Claims77.0
Peer Average 30-Day Fills123.2
Peer Average Days Supply3,403
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $93,620.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,170.25

State Avg Cost Per Claim

$792.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Flecainide Acetate

Generic Formulation: Flecainide AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 52.0
Days Supply 1,560
MA State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills84.9
Peer Average Days Supply2,526
Conservative Utilization

This provider writes prescriptions for this formulation 47.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,267.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$70.41

State Avg Cost Per Claim

$70.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.

Therapeutic Applications

This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as sustained ventricular tachycardia and paroxysmal supraventricular tachycardia). It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. It is also used to prevent certain types of irregular heartbeat from returning (such as atrial fibrillation). Flecainide is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat. Treating an irregular heartbeat can decrease the risk for blood clots, and this effect can reduce your risk of heart attack or stroke. Older adults should discuss the risks and benefits of this medication with their doctor or pharmacist, as well as other effective and possibly safer treatments.

Metoprolol Succinate

Generic Formulation: Metoprolol SuccinateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 63
30-Day Fills 161.7
Days Supply 4,850
MA State Average Benchmarks
Peer Average Claims106.0
Peer Average 30-Day Fills250.9
Peer Average Days Supply7,421
Conservative Utilization

This provider writes prescriptions for this formulation 40.6% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,813.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.65

State Avg Cost Per Claim

$23.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.

Therapeutic Applications

This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 30.0
Days Supply 900
MA State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills75.1
Peer Average Days Supply2,116
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.0% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $17,546.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$974.82

State Avg Cost Per Claim

$930.26

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. LINDA ANN COTTER NP-C provides transparency into local medical care patterns within Boston, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Adult Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.